• Tempus AI outlined a strategy to pair AI-enabled diagnostics with embedded clinical distribution to scale precision medicine across care and drug development.
• Operating metrics as of 3/31/2026: ~65% of US academic medical systems connected, >55% of US oncologists reached, 5,000+ institutions.
• Data scale as of 3/31/2026: 500+PB multimodal dataset, >45 million de-identified patient records, >4.5 million samples sequenced.
• Diagnostics throughput as of 3/31/2026: ~1 million NGS tests run annually across four labs, ~4,000 employees.
• Clinical evidence highlights: DNA+RNA sequencing identified 21% more patients with driver fusions tied to FDA-approved targeted therapies versus DNA alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.